Looking to expand its mRNA franchise, Pfizer (NYSE:PFE) announced a pact with Acuitas, which specializes in lipid nanoparticle (LNP) formulation technology. The deal allows Pfizer to license Acuitas’ LNP technology in up to 10 targets for vaccine or therapeutic development. Pfizer and its partner BioNTech currently use Acuitas’ LNP in their Comirnaty COVID-19 vaccine. Pfizer…
Canadian federal advisory committee prefers mRNA COVID-19 vaccines
Canada’s National Advisory Council on Immunization (NACI) has recommended that Canadians wait to receive the messenger RNA (mRNA) vaccines from Moderna (NSDQ:MRNA) and Pfizer (NYSE:PFE) and BioNTech (NSDQ:BNTX) when feasible. The advice stands in contrast to prior guidance that Canadians seek the first-available vaccines. “What we’re saying and what we’ve said all along is that mRNA vaccines are the…